Thursday 25 October 2012
Dairy cows health
A special formulation of Fasinex fluckicide for use in dairy cows has been launched on the Irish market.
The Irish Medicines Board has granted Novartis Animal Health a licence for the use of Fasinex 240 in dairy cows that will produce milk for human consumption.
The licence followed on from a successful application to the EU Commission for a maximum residue limit for triclabendazole (the active ingredient in Fasinex), against which residue concentrations could be evaluated.
Novartis then carried out a study on milk residues in pregnant dry cows after Fasinex 240 was given 28 to 42 days before the calculated calving date.
Consequently, milk for human consumption can be taken from 48 hours after calving, if the animals were treated at least 35 days before calving. If calving occurs within 35 days treatment, milk can be taken only after 35 days plus 48 hours.
Fasinex is active against adult, immature and early immature fluke. Since March 2010, only products active against adult fluke were permitted for use in dairy cows and dairy heifers, leading to the requirement for two doses separated by an interval.
Fasinex 240 is administered in one concentrated low- volume oral dose.
Back to News Headlines